ABOUT IMMUNO CURE

Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.

Milestones

2015	Immuno Cure Limited was formed in Hong Kong, China
2016	Exclusive license and collaboration agreement was signed with The University of Hong Kong Technology Transfer Office (HKU TTO) for ICVAX
2017	Shenzhen Immuno Cure Biotechnology Limited (深圳医克生物科技有限公司) was established in Shenzhen, China
2018	Exclusive license and collaboration agreement was signed with HKU TTO for Anti-PD-1 Isoform Antibody
2019	Engaged a GMP manufacturer and a GLP laboratory for vaccine manufacturing, animal efficacy and safety evaluation of ICVAX
2020	1. Exclusive license agreement was signed with HKU TTO for ICCOV 2. Engagement of a GMP manufacturer and a GLP laboratory for manufacturing and animal tests of ICCOV
2021 April	1. IND enabling stage of ICVAX and ICCOV 2. Setup R&D Laboratory in HK Science Park
2021 May	Completion of Seed 2 round fundraising
2021 November	Collaboration with HKU and obtained approval from Department of Health for conducting phase 1 clinical trial of ICCOV in HK Queen Mary Hospital
2021 December	Acquisition of a HKSTP company - Pure Innovation Biotech Limited, to develop the plasmid delivery technology and DNA vaccine manufacturing process technology
2022 May	Obtained IND approval from the National Medical Products Administration (NMPA) for conducting a phase 1 clinical trial of ICVAX in Mainland China.